GLGC Gene Logic Inc. (MM)

Gene Logic Inc. (NASDAQ:GLGC) today announced the completion of significant enhancements to its industry-leading gene expression capabilities, used by pharmaceutical and academic researchers to characterize drug targets and understand the relationship between gene expression and disease. The combination of a microarray upgrade, acquisition of new human data from the array, increased use of robotics, and improvement of the company's proprietary integrated data management tool provide one of the highest quality platforms available for gene expression study. Gene Logic's customers will benefit from the new systems in several ways: -- The Affymetrix GeneChip(R) Human Genome U133 Plus 2.0 Array is the industry's most broadly used human microarray, offers increased accuracy and reproducibility, and uses less sample RNA than its predecessors. -- Guided by customer feedback, Gene Logic ran more than 10,000 of the most in-demand human samples on the new microarray to significantly increase the content of the Company's proprietary BioExpress(R) System, one of the largest commercially available gene expression databases in the world. Additionally, the company runs all new human samples on the new array and incorporates the data in the BioExpress System. -- Gene Logic's Microarray Data Generation and Analysis Services now generate highly reproducible genomic data from the new array in a high-throughput, robotic environment. -- For superior analysis of the new human gene expression data, Gene Logic recently expanded its GX(R) Gene Index to include several million updated gene and protein annotations as well as more than 650 biological pathways, most of which are exclusive to Gene Logic through an agreement with BioCarta. Lianne McLean, senior director, Product Marketing at Affymetrix said, "For the last seven years, Affymetrix and Gene Logic have been working together to help researchers better understand the relationship between gene expression and disease. With the addition of the GeneChip Human Genome U133 Plus 2.0 Array, Gene Logic customers will have access to both the gold-standard microarray technology and the industry leading expression database." Dennis Rossi, senior vice president and general manager, Genomics for Gene Logic, said, "To meet the changing needs of our customers and continue to provide the high-quality gene expression and SNP genotyping services they demand, Gene Logic has improved one of the largest commercial microarray labs in the world. Guided by our prior experience gained from processing more than 170,000 microarrays, we refined our operations using robotics, high-throughput process automation, and strict quality metrics. As a result of upgrading our content and expanding our microarray production facilities, we now offer these expanded capabilities to pharmaceutical, biotech, and government customers to outsource data generation and analysis work." Gene Logic Overview Gene Logic is leading the transformation of pharmaceutical research and development with its extensive gene expression databases, pioneering efforts in toxicogenomics, sophisticated bioinformatics expertise, specialty nonclinical services testing capabilities and cutting edge technology program for drug repositioning. Gene Logic technologies and services are used by many of the world's top pharmaceutical and biotechnology companies. Over 150 organizations and government agencies have benefited from Gene Logic's diverse portfolio of drug development services, enabling them to make more informed, more reliable and more predictive decisions at each point in the highly complex and costly drug development process. Founded in 1994, Gene Logic is headquartered in Gaithersburg, Maryland, with additional research and development facilities in Cambridge, Massachusetts, and Berkeley, California. The Company maintains customer support operations in Europe and Asia and currently has about 450 employees worldwide. For more information, visit www.genelogic.com or call toll-free - 1/800/GENELOGIC.